Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.
Fundamentals
Mkt Cap
$39.64B
Volume
-
52W High
$437.41
52W Low
$181.00
PE Ratio
-238.51
Avg. Volume
1.61M
EPS (Annual)
-$1.52
P/B
21.11
Rev/Employee
$375,588.44
Earnings
Nov 05
61
Bullish Sentiment
How do you feel about NTRA?
1986iamwallstreet
$NTRA CEO or should I say as of today EX-CEO has been selling he made sure to get out at the top 🩸🩸🩸🩸🩸🩸🩸🩸🩸🩸🩸🩸🩸🩸🩸🩸🩸
2
2
BioHunter1
$NTRA $CYDY Think about it! 10share of NTRA can get you 15,765 shares of CYDY as of Friday’s close..
6
openclassaction2
$NTRA the $9.5 million natera billing settlement is open, claim by may 3, 2027, per open class actions. suit alleges patients were billed over the promised threshold. seems like billing bills come due
1
1
shoc24
$NTRA is ranked #15 in healthcare momentum with a score of 86. I posted these rankings yesterday, but I think they're worth sharing again. I bought yesterday because money is made when the markets are down. I used Stock Meadow's scoring model to find what I'm buying.
4
Dr_Stoxx
The diagnostics space has been hot hot hot. We bankeda nice win in $NTRA in the Live Trading Room. Had $ILMN unofficially (ER tonight). $IQV also good among others:
3
SilverEagle
$NTRA printing money like the Fed feels niceee. Don’t forget to sign up for my alerts. Oh wait lol
3
Pavie99
$NTRA 🤣 🤣 🤣 Wait til they start reporting 💩 💩 sales and lose of market share. This thing will not see 300 again, let alone 400 😂 This is the Comcast of diagnostics...not hard to compete when nobody is there to fight. Now with all these MRDs and better tech entering the market this will continue to erode. In the meantime tho pave the way for the other MRDs that will replace you.
1
sSwSs
$NTRA — NTRA's recent reports focused on a significant price drop following a CEO transition, despite a Q3 revenue beat and raised outlook.
2
openclassaction2
$NTRA: check the first letter of your Class Member ID in Calcaterra. A means Natera records show you paid over the threshold and share 94.7% of the net fund. B caps at $50. Claim by May 3, 2027. Open Class Actions.
2
Dr_Stoxx
$NTRA goes on greens list. This is a good example of what can work until we get past midterms: strong uptrend, consolidation at/near highs, above all MA's, indicators not OB, and ER not immediate.
2
Arcides
$NTRA last rally went from 275 to 437...is very close to totally reverse it...not good signal
1
openclassaction2
$NTRA the $9.5 million natera billing settlement is open, up to $50, claim by may 3 2027, per open class actions. suit alleges patients were not clearly told out of pocket costs
1
algotradealert
$NTRA: revenue +34.1% to $794M. Oncology tests +60.9%.
Yet the quarter still produced a $59.9M GAAP net loss.
What deserves more attention: rapid test adoption or the path to profitability?
1
invisiblesurfer
$NTRA well from your screenshot it looks like he sold like 13,000 shares and he's still holding 87,000 shares...
1
Cheetah007
$NTRA just wait until Myriad or labcorp... or somebody start running the same test. They haven't yet to figure a way to be profitable by then.
StocktwitsEarnings
$NTRA Q3 '26 Earnings Results & Recap
• Reported GAAP EPS of -$0.42 up 34.38% YoY
• Reported revenue of $793.98M up 34.08% YoY
• Natera anticipates 2026 total revenue of $3.01B to $3.04B, gross margin of approximately 64% to 66%, SG&A costs of approximately $1.23B to $1.3B, R&D costs of $825M to $925M, and positive cash flow.
Link your Stocktwits account
Ask your agent for live sentiment, watchers, trending tickers, and news.